Ebiratide (Hoe 427) is a peptide analog of corticotrophin (ACTH 4-9). Ebiratide is endocrinologically inert. Ebiratide is highly lipophilic and has prolonged metabolic stability. Ebiratide exerts neurotrophic properties in vivo. It also was proven to have significant effects on acetylcholine metabolism. It has been investigated in the treatment of Alzheimer's disease.

Camonagrel is a novel selective thromboxane synthetase inhibitor patented by Ferrer Internacional S. A. Camonagrel reduced platelet-subendothelium interaction under flow conditions, showing this effect in a range of concentrations lower than in inhibition of platelet aggregation.

Nuclomedone (TEI-3096), a thiazolopyrimidine compound has been shown to suppress adjuvant arthritis in rats without any effect on conventional inflammation. TEI-3096 also enhanced the delayed type hypersensitivity in mice and rats. These results suggests that TEI-3096 restores the abnormal immune response. Nuclomedone was discovered by Teijin and investigated as a potential treatment for rheumatoid arthritis and inflammatory disorders.

Rofleponide is a third generation synthetic glucocorticosteroid. This compound has high affinity for the rat thymus glucocorticoid receptor and showed a very high biotransformation rate in the human liver. Rofleponide was being investigated for its anti-inflammatory, immunosuppressive and anti-anaphylactic activity. It was evaluated in phase II clinical trials for its safety and efficacy in allergic rhinitis and asthma, and in a preclinical study for use in inflammatory bowel disease, but development of this drug was discontinued. Rofleponide was never marketed.

Oxeglitazar (also known as EMD 336340 or LM 4156), an orally administered poorly water-soluble dual peroxisome proliferator-activated receptor α/γ agonist. This drug was used in the treatment of type II diabetes mellitus and metabolic syndrome. In addition, oxeglitazar participated in phase I trials for the gout treatment; however, this study was halted. Information about the further development of this drug is not available.

Tarafenacin (also known as SVT-40776) was developed as muscarinic M3 receptor antagonist for the treatment of overactive bladder. The drug participated in phase II clinical trial in patients suffering from overactive bladder, where both dose levels of tarafenacin were well tolerated. However, information about the further development of tarafenacin is not available.

Piclopastine is an antihistamine agent.